Apogee Therapeutics, Inc. (APGE)
After hours:
| Previous close | 53.34 |
| Open | 55.00 |
| Bid | 52.75 x 100 |
| Ask | 53.07 x 100 |
| Day's range | 52.63 - 55.00 |
| 52-week range | 14.19 - 72.29 |
| Volume | |
| Avg. volume | 434,658 |
| Market cap | 3.001B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE)
The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 280,793 shares of Apogee Therapeutics Inc. Apogee Therapeutics Inc (NASDAQ:APGE) is a biopharmaceutical company focused on the development and commercialization of novel therapies to treat autoimmune and inflammatory diseases.
- GuruFocus.com
Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE)
The transaction was documented in an SEC Filing. Following this sale, the insider now owns 200,871 shares of Apogee Therapeutics Inc. Apogee Therapeutics Inc is engaged in the development and commercialization of various therapies aimed at treating diseases with significant unmet medical needs.
- GuruFocus.com
Apogee Therapeutics Inc (APGE) CEO Michael Henderson Sells 40,000 Shares
The transaction was disclosed in a recent SEC Filing. Apogee Therapeutics Inc is engaged in the development and commercialization of various therapies aimed at treating diseases with significant unmet medical needs. Over the past year, Michael Henderson has sold a total of 55,000 shares and has not made any purchases of stock in the company.
